The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Romanov D.V.
Sechenov First Moscow State Medical University (Sechenov University);
Mental Health Research Center
Samsonova M.D.
Sechenov First Moscow State Medical University (Sechenov University)
Yuzbashyan P.G.
Sechenov First Moscow State Medical University (Sechenov University)
Treatment of mental disorders caused or triggered by somatic and neurological diseases with the use of the multimodal antidepressant trazodone
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(4‑2): 81‑89
Views: 3791
Downloaded: 60
To cite this article:
Romanov DV, Samsonova MD, Yuzbashyan PG. Treatment of mental disorders caused or triggered by somatic and neurological diseases with the use of the multimodal antidepressant trazodone. S.S. Korsakov Journal of Neurology and Psychiatry.
2023;123(4‑2):81‑89. (In Russ.)
https://doi.org/10.17116/jnevro202312304281
The purpose of this narrative review is to relate current data on the molecular mechanisms of action of trazodone with its clinical effects and applicability in mental disorders caused or triggered by somatic and neurological disease, according to available publications. In the article, the prospects for the use of the multimodal antidepressant trazodone are discussed in accordance with therapeutic targets. The latter are discussed in accordance with the typology of the mentioned above psychosomatic disorders. Trazodone is an antidepressant acting primarily due to the blockade of postsynaptic serotonin 5H2A- and 5H2C-receptors, as well as the blockade of serotonin reuptake, but also has affinity for a number of additional receptors. The drug has a favorable safety profile and a wide range of beneficial effects: antidepressive, somnolent, anxiolytic, anti-dysphoric and somatotropic. This makes it possible to influence a wide range of therapeutic targets in the structure of mental disorders caused or triggered by somatic and neurological diseases, carrying out safe and effective psychopharmacotherapy.
Keywords:
Authors:
Romanov D.V.
Sechenov First Moscow State Medical University (Sechenov University);
Mental Health Research Center
Samsonova M.D.
Sechenov First Moscow State Medical University (Sechenov University)
Yuzbashyan P.G.
Sechenov First Moscow State Medical University (Sechenov University)
Received:
15.02.2023
Accepted:
15.03.2023
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.